vs
OR Royalties Inc.(OR)与RHYTHM PHARMACEUTICALS, INC.(RYTM)财务数据对比。点击上方公司名可切换其他公司
RHYTHM PHARMACEUTICALS, INC.的季度营收约是OR Royalties Inc.的1.3倍($60.1M vs $46.7M)
OR Royalties Inc.是一家加拿大矿业特许权企业,持有金矿、银矿及钻石矿的特许权权益,主要以冶炼厂净回报权和金属流形式运营。其前身为奥西斯科矿业,总部位于魁北克省蒙特利尔,股票在多伦多证券交易所及纽约证券交易所挂牌交易。
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业,主要开发和商业化针对罕见遗传性肥胖症的靶向疗法,覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症,服务北美、欧洲地区缺少有效治疗方案的患者群体。
OR vs RYTM — 直观对比
营收规模更大
RYTM
是对方的1.3倍
$46.7M
损益表 — Q2 FY2022 vs Q1 FY2026
| 指标 | ||
|---|---|---|
| 营收 | $46.7M | $60.1M |
| 净利润 | — | $-55.6M |
| 毛利率 | — | 88.1% |
| 营业利润率 | — | -87.1% |
| 净利率 | — | -92.6% |
| 营收同比 | — | 83.8% |
| 净利润同比 | — | — |
| 每股收益(稀释后) | — | $-0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
OR
RYTM
| Q1 26 | — | $60.1M | ||
| Q4 25 | — | $57.3M | ||
| Q3 25 | — | $51.3M | ||
| Q2 25 | — | $48.5M | ||
| Q1 25 | — | $32.7M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | — | $33.3M | ||
| Q2 24 | — | $29.1M |
净利润
OR
RYTM
| Q1 26 | — | $-55.6M | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | — | $-52.9M | ||
| Q2 25 | — | $-46.6M | ||
| Q1 25 | — | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | — | $-43.6M | ||
| Q2 24 | — | $-32.3M |
毛利率
OR
RYTM
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
营业利润率
OR
RYTM
| Q1 26 | — | -87.1% | ||
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | — | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | — | -139.2% |
净利率
OR
RYTM
| Q1 26 | — | -92.6% | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | — | -103.1% | ||
| Q2 25 | — | -96.1% | ||
| Q1 25 | — | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | — | -131.2% | ||
| Q2 24 | — | -110.9% |
每股收益(稀释后)
OR
RYTM
| Q1 26 | — | $-0.83 | ||
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | — | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | — | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | — | $340.6M |
| 总债务越低越好 | $222.8M | — |
| 股东权益账面价值 | $1.3B | $122.9M |
| 总资产 | — | $442.3M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势,按日历期对齐
现金及短期投资
OR
RYTM
| Q1 26 | — | $340.6M | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
股东权益
OR
RYTM
| Q1 26 | — | $122.9M | ||
| Q4 25 | — | $139.1M | ||
| Q3 25 | — | $148.8M | ||
| Q2 25 | — | $-11.9M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | — | $11.2M | ||
| Q2 24 | — | $39.3M |
总资产
OR
RYTM
| Q1 26 | — | $442.3M | ||
| Q4 25 | — | $480.2M | ||
| Q3 25 | — | $506.9M | ||
| Q2 25 | — | $372.7M | ||
| Q1 25 | — | $386.7M | ||
| Q4 24 | — | $392.3M | ||
| Q3 24 | — | $363.6M | ||
| Q2 24 | — | $381.8M |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图